Pd71-06 Ctc-based Gene Expression for Predicting Resistance to Abiraterone and Enzalutamide in Mcrpc
Year: 2017
Type: article
Abstract: prostate cancer, and compared it to a base model consisting of age, digital rectal exam findings, and PSA.Additionally, we compared the performance of the 4Kscore test in AA and non-AA men.RESULTS: Among 403 men who were enrolled in the trial, we had 366 men with a 4Kscore and complete data available for analysis.Among these men, 208 (56%) were AA, and 134 (36%) had G7+ prostate cancer.The 4Kscore exhibited better discrimination (AUC: 0.81 vs. 0.74, p¼0.011) and higher clinical utility on decision analysis than the base model for deciding on the need for biopsy.Calibration plots of the 4Kscore for the entire cohort afforded predictions that closely matched the observed risk of G7+ prostate cancer in the population (Figure 1).There was no difference in the discrimination of the 4Kscore test between AA and non-AA men (0.80 vs. 0.84; p¼0.32).While we found some evidence that the 4Kscore underestimates the risk of G7+ prostate cancer in AA men, discrimination (0.80 vs. 0.72, p ¼ 0.013) and clinical utility for the 4Kscore test were still higher than the base model.CONCLUSIONS: In an independent, multi-institutional, prospective trial of the 4Kscore test in the VA health system, we confirmed that the 4Kscore accurately predicts the likelihood of aggressive prostate cancer and outperforms standard clinical information for biopsy decision making in both AA and non-AA men.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2604137663